Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Seeks New R&D Tax Credit Scheme for Strategic Technologies in FY2026 Proposal
Japan’s Ministry of Health, Labor and Welfare (MHLW) on August 26 released its requests for the FY2026 tax reform, calling for the creation of a new scheme that would grant preferential deduction rates and ceilings for R&D in technologies deemed…
To read the full story
Related Article
- Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026
- Heparinoid, Allergy Drugs among OTC-Like Meds Up for Special Charge Rule
December 24, 2025
- LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
- LDP, Ishin Finalize FY2026 Tax Reform Outline, Strategic Tech R&D Credit Codified
December 22, 2025
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
- Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- R&D Tax Credit Draws Broad Calls for Maintenance, Expansion: LDP Meeting
December 8, 2025
- Ishin Urges Takaichi to Revisit OTC-Like Drug Coverage, Softens Savings Target
December 5, 2025
- JPMA Chief Presses LDP Study Group to Lock In On-Patent Prices, Scrap “Spillover” Rule
December 5, 2025
- LDP, Ishin to Continue OTC-Like Drug Talks on “Special Charge” Design
December 5, 2025
- LDP Tax Panel Puts R&D Tax Credit on Political-Judgment Track for Further Talks
December 3, 2025
- As Skepticism Emerges, LDP Health Policy Chief Seeks Stronger R&D Tax Credits
November 28, 2025
- LDP Study Group Submits Emergency Proposal to Health Minister, Seeks 5% Drug Price Hike
November 19, 2025
- Pharma, Wholesalers Urge Drug Pricing Overhaul to Address Inflation: LDP Hearing
November 13, 2025
- No Inflation Measures for Drugs Mentioned in FY2026 Budget Request: MHLW Draft
August 25, 2025
- Japan Mulls Preferential R&D Tax Credits for Strategic Technologies in FY2026 Reform Talks
August 22, 2025
- Ruling Parties OK FY2023 Tax Reform Outline; No More Special COVID Measure for R&D Credits
December 19, 2022
REGULATORY
- MHLW Panel Calls for Careful Design of OTC-Like Drug Charge System
March 23, 2026
- Japan Hands Out Orphan Tags to Ianalumab, Bleximenib, and Lots More Drugs
March 23, 2026
- Ex-LDP Lawmaker, Pharmacist Jun Matsumoto Dies at 75
March 23, 2026
- LDP Project Team Flags Drug Pricing as Key to Investment
March 19, 2026
- Japan Sets Up Radiopharma Discovery Hub in Fukushima, Targets Rare Cancers
March 18, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…